Royalty Pharma plc Profit Margin

Royalty Pharma plc (RPRX) currently reports a profit margin of 33.9% as of March 2026. That compares with 48.25% in the prior-year period — down 29.7% year over year. That is above the Healthcare sector average of 15.58%. Use the charts on this page to explore Royalty Pharma plc's profit margin history and peer comparisons.

Royalty Pharma plc's profit margin decreased from 48.25% to 33.9% — a 29.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Royalty Pharma plc's profit margin of 33.9% is higher than the Healthcare sector average of 15.58%. That is roughly 117.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Royalty Pharma plc's current 33.9% should be judged against Healthcare norms (sector average: 15.58%) and against RPRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 33.9%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Royalty Pharma plc, and consider following RPRX for alerts when major investors trade the stock.